USA - NASDAQ:LENZ - US52635N1037 - Common Stock
The current stock price of LENZ is 41.26 USD. In the past month the price increased by 3.15%. In the past year, price increased by 71.63%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 46.75 | 714.53B | ||
JNJ | JOHNSON & JOHNSON | 17.42 | 419.56B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 15.45 | 269.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.45 | 240.29B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.94 | 238.81B | ||
MRK | MERCK & CO. INC. | 10.44 | 200.82B | ||
PFE | PFIZER INC | 7.09 | 136.68B | ||
SNY | SANOFI-ADR | 10.56 | 114.66B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.68 | 91.55B | ||
GSK | GSK PLC-SPON ADR | 9.05 | 82.42B | ||
ZTS | ZOETIS INC | 23.26 | 64.11B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.76 | 47.40B |
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ THERAPEUTICS INC
201 Lomas Santa Fe Drive, Suite 300
Solana Beach CALIFORNIA US
Employees: 42
Phone: 18589257000
The current stock price of LENZ is 41.26 USD. The price decreased by -2.39% in the last trading session.
The exchange symbol of LENZ THERAPEUTICS INC is LENZ and it is listed on the Nasdaq exchange.
LENZ stock is listed on the Nasdaq exchange.
14 analysts have analysed LENZ and the average price target is 50.71 USD. This implies a price increase of 22.9% is expected in the next year compared to the current price of 41.26. Check the LENZ THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LENZ THERAPEUTICS INC (LENZ) has a market capitalization of 1.18B USD. This makes LENZ a Small Cap stock.
LENZ THERAPEUTICS INC (LENZ) currently has 42 employees.
LENZ THERAPEUTICS INC (LENZ) has a support level at 37.48 and a resistance level at 42.28. Check the full technical report for a detailed analysis of LENZ support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LENZ does not pay a dividend.
LENZ THERAPEUTICS INC (LENZ) will report earnings on 2025-11-10, after the market close.
LENZ THERAPEUTICS INC (LENZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.88).
The outstanding short interest for LENZ THERAPEUTICS INC (LENZ) is 17.85% of its float. Check the ownership tab for more information on the LENZ short interest.
ChartMill assigns a technical rating of 10 / 10 to LENZ. When comparing the yearly performance of all stocks, LENZ is one of the better performing stocks in the market, outperforming 91.9% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to LENZ. While LENZ has a great health rating, there are worries on its profitability.
Over the last trailing twelve months LENZ reported a non-GAAP Earnings per Share(EPS) of -1.88. The EPS increased by 80.13% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.11% | ||
ROE | -25.39% | ||
Debt/Equity | 0 |
14 analysts have analysed LENZ and the average price target is 50.71 USD. This implies a price increase of 22.9% is expected in the next year compared to the current price of 41.26.